Navigation Links
Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine
Date:6/7/2012

WORCESTER, Mass. and TORONTO, June 7, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) announced today that an End-of-Phase II meeting has been scheduled with the United States Food and Drug Administration (FDA) in respect of the Phase II clinical trial of the AE37 breast cancer vaccine being undertaken by its wholly-owned subsidiary, Antigen Express, Inc.

The meeting has been scheduled for June 18, 2012 with FDA regulatory management staff in the Office of Cellular Tissues and Gene Therapies in the Center for Biologics Evaluation and Research.  Antigen Express has provided the FDA with a comprehensive and detailed package regarding the AE37 breast cancer vaccine, the on-going Phase II clinical trial, and the company's plans for a transition into a pivotal Phase III trial.

Antigen Express will solicit guidance from the FDA regarding the company's proposed structure of a pivotal Phase III trial.

In addition to representatives of Antigen Express, Dr. Samuel Jacobs, MD, Director, Medical Affairs, National Surgical Adjuvant Breast and Bowel Project (NSABP) and a member of the Antigen Express AE37 breast cancer Scientific Advisory Board (SAB), will attend the meeting to proffer his advice and assistance on behalf of Antigen Express.  The NSABP is a clinical trials cooperative group supported since its inception by the National Cancer Institute (NCI). It has a more than 50-year history of designing and conducting clinical trials that have changed the way breast cancer is treated, and, more recently, prevented.  The NSABP was the first to demonstrate that adjuvant therapy could alter the natural history of breast cancer.  Since its inception, the NSABP has enrolled more than 110,000 women and men in clinical trials in breast and colorectal cancer.  It has research sites at nearly 1000 major medical centers, university hospitals, large oncol
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
2. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
3. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
4. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
5. Generex Secures Commitments for $3.6M Capital Raise
6. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
7. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
8. Generex Announces Date of Annual Stockholders Meeting
9. Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
11. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... 2014 An analysis by Replikins, Ltd. of ... Mers CoV virus strains has revealed extensive conservation ... This conservation and sharing of specific Replikin gene structures ... candidate, as it did for the H5N1 influenza vaccine ... have been found to be effective (1,2). ...
(Date:8/26/2014)... , August 26, 2014 , ... hospitals with surgery validation using its Stratasys Objet24 and Objet30 ... surgery on 3D printed models prior to operations reduces theatre ... effective aid for both patient and surgeon   ... a global leader of 3D printing and additive manufacturing solutions, ...
(Date:8/26/2014)... AVENTURA. Fla. , Aug. 26, 2014 /PRNewswire/ ... trades under the symbol (NUUU) has two (2) ... Inc. Our two subsidiaries harness scientifically advanced technology ... NUUU,s Renuell Int,l, Inc. ... breakthrough anti-aging skin care products that is made ...
(Date:8/26/2014)... , Aug. 26, 2014 Trovagene, Inc. ... Generation Dx Summit; Moving Assays to the Clinic ... and Monitoring of Cell Free Tumor DNA in ... component of its Precision Cancer Monitoring (PCM) platform ... sensitivity for the detection of tumor DNA mutations ...
Breaking Biology Technology:Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 3Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 5Technology Applications International Corporation, Trading Symbol NUUU now trading on NASDAQ's Over the Counter Bulletin Board (OTC BB) 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 4
... TELK ) announced that its 2008 second quarter ... 11, 2008 at 4:30 p.m. Eastern time,(1:30 p.m. Pacific ... financial results for the second quarter ended June 30, ... Telik,s website at, http://www.telik.com or by telephone at ...
... Aug. 4 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group ... Bio-Tech Products (Shandong) Co., Ltd. (Kiwa Shandong),has ... China Organic Food,Certification Center (COFCC)., After ... appraisal of,Kiwa Shandong,s products, the China Organic ...
... Share Proposal is Best and Final Offer, INDIANAPOLIS, ... ) today reaffirmed that its $3.00 per share purchase ... its best and final offer,for the San Diego-based biotechnology ... signing of a definitive merger agreement, whereby,Lilly will acquire ...
Cached Biology Technology:Kiwa Bio-Tech Receives Nationally Recognized Organic Products Certification 2Kiwa Bio-Tech Receives Nationally Recognized Organic Products Certification 3Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 2Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 3
(Date:8/26/2014)... increased risk of autism among children of women ... the known increased risk associated with severe maternal ... publication in Molecular Psychiatry , investigators from ... a diagnosis of autism spectrum disorder was more ... during pregnancy than in those with no prenatal ...
(Date:8/25/2014)... has experienced widespread adoption of robot-assisted prostate removal ... The BJU International study also found ... traditional surgeries, their costs are decreasing over time. ... in operations to remove the prostate. To examine ... prostatectomy (RARP) procedures for prostate cancer patients, Steven ...
(Date:8/25/2014)... Diego School of Medicine have found one of the ... a deadly brain cancer are resistant to drug therapy. ... tumor, but in its epigenetic signature. These findings have been ... Oncotarget . , "There is a growing interest to ... cell," said Clark Chen, MD, PhD, vice-chairman of Research and ...
Breaking Biology News(10 mins):Study calls into question link between prenatal antidepressant exposure and autism risk 2Study calls into question link between prenatal antidepressant exposure and autism risk 3US has seen widespread adoption of robot-assisted cancer surgery to remove the prostate 2Finding keys to glioblastoma therapeutic resistance 2
... at the Texas A&M Health Science Center Institute ... Edinburgh have uncovered how a bacterial pathogen interacts ... methicillin-resistant Staphylococcus aureus (MRSA) infections, a ... the potentially deadly disease. Their work appears ...
... the wrong times, the results can be genetic disaster. ... in fruit flies that yank chromosomes, the DNA-carrying structures, ... condensin II, separate chromosomes by twisting them into supercoils ... Scientists had known of condensin II but did ...
... ON A new and insidious environmental threat ... researchers from Queen,s and York universities. Along ... team has documented biological damage caused by declining ... Calling the phenomenon "aquatic osteoporosis," Queen,s PhD ...
Cached Biology News:Keeping chromosomes from cuddling up 2Keeping chromosomes from cuddling up 3Queen's University biologists find new environmental threat in North American lakes 2
Acetylcholinesterase from human and monkey....
...
... Dye runs faster than Bromophenol blue,or ... gels.,Orange G dye migrates with DNA ... migration at this size,prevents the obscuring ... the front of DNA migration.,The Orange ...
... Gel loading solution, ... for non-denaturing polyacrylamide and ... nucleic acids and offers ... tracking dyes (bromphenol blue ...
Biology Products: